Hennion & Walsh Asset Management Inc. Cuts Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Hennion & Walsh Asset Management Inc. lessened its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 35.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 13,910 shares of the company's stock after selling 7,740 shares during the period. Hennion & Walsh Asset Management Inc.'s holdings in Krystal Biotech were worth $2,532,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Jamison Private Wealth Management Inc. acquired a new stake in shares of Krystal Biotech during the second quarter worth $28,000. GAMMA Investing LLC grew its holdings in Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company's stock worth $28,000 after acquiring an additional 93 shares during the period. Key Financial Inc bought a new position in shares of Krystal Biotech in the 2nd quarter worth about $28,000. Blue Trust Inc. lifted its stake in shares of Krystal Biotech by 2,328.6% in the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company's stock valued at $30,000 after purchasing an additional 163 shares during the period. Finally, Quest Partners LLC bought a new stake in shares of Krystal Biotech during the 2nd quarter valued at about $71,000. Institutional investors own 86.29% of the company's stock.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock traded up $0.53 during trading hours on Friday, reaching $175.51. The company's stock had a trading volume of 129,171 shares, compared to its average volume of 331,355. The company has a market capitalization of $5.04 billion, a P/E ratio of 48.09 and a beta of 0.82. The stock's fifty day simple moving average is $185.29 and its two-hundred day simple moving average is $179.94. Krystal Biotech, Inc. has a one year low of $93.95 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.53 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.03. The business had revenue of $70.28 million for the quarter, compared to analysts' expectations of $65.27 million. Krystal Biotech had a net margin of 63.73% and a return on equity of 1.99%. The firm's revenue for the quarter was up 70283900.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.25) EPS. As a group, research analysts forecast that Krystal Biotech, Inc. will post 3.13 earnings per share for the current year.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total value of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares of the company's stock, valued at approximately $296,814,424.32. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 14.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on KRYS. Chardan Capital lifted their target price on Krystal Biotech from $153.00 to $208.00 and gave the stock a "buy" rating in a report on Monday, August 5th. Stifel Nicolaus lifted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research note on Wednesday, September 11th. Citigroup reissued a "neutral" rating and set a $204.00 target price (up from $195.00) on shares of Krystal Biotech in a research note on Tuesday, August 6th. Evercore ISI raised their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an "outperform" rating in a report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a report on Thursday, August 29th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $196.75.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).